l-Scoulerine attenuates behavioural changes induced by methamphetamine in zebrafish and mice

Behavioural Brain Research

Volumn 298, Issue , 2016, Pages 97-104

  Mi, Guiyun ^a   Gao, Yunyun ^a   Yan, Hui ^b   Jin, Xiao ^a   Ye, Enmao ^a   Liu, Shuai ^a   Gong, Zehui ^b   Yang, Hongju ^a   Yang, Zheng ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

Conditioned place preference; Methamphetamine; Sensitization; Zebrafish

Indexed keywords

ALKALOID; BERBINE DERIVATIVE; LEVO SCOULERINE; METHAMPHETAMINE; UNCLASSIFIED DRUG; BERBERINE DERIVATIVE; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL STIMULANT AGENT; DISCRETAMINE;

ADDICTION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR CHANGE; CONDITIONED PLACE PREFERENCE TEST; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; FEMALE; LOCOMOTION; LONG TERM EXPOSURE; MALE; MOUSE; MOVEMENT (PHYSIOLOGY); NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; STRUCTURE ANALYSIS; SWIMMING; TIME; TRANQUILIZING ACTIVITY; TREATMENT FAILURE; ZEBRA FISH; AMPHETAMINE DEPENDENCE; ANIMAL; ANXIETY DISORDERS; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PSYCHOLOGY; RANDOMIZATION; SPATIAL BEHAVIOR;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; ANXIETY DISORDERS; BERBERINE ALKALOIDS; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; DISEASE MODELS, ANIMAL; FEMALE; MALE; METHAMPHETAMINE; MICE; MOTOR ACTIVITY; RANDOM ALLOCATION; SPATIAL BEHAVIOR; ZEBRAFISH;

EID: 84949033339     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.09.039     Document Type: Article

References (58)

1. Akindipe T., Wilson D., Stein D.J. Psychiatric disorders in individuals with methamphetamine dependence: prevalence and risk factors. Metab. Brain Dis. 2014, 29:351-357.
2. Rusyniak D.E. Neurologic manifestations of chronic methamphetamine abuse. Psychiatr. Clin. North Am. 2013, 36:261-275.
3. Chiu V.M., Schenk J.O. Mechanism of action of methamphetamine within the catecholamine and serotonin areas of the central nervous system. Curr. Drug Abuse Rev. Sep. 2012, 5(3):227-242.
4. Simon P., Panissaud C., Costentin J. Anxiogenic-like effects induced by stimulation of dopamine receptors. Pharmacol. Biochem. Behav. 1993, 45:685-690.
5. Simon P., Dupuis R., Costentin J. Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions. Behav. Brain Res. 1994, 61:59-64.
6. Pometlová M., Noheilová-Devkun K., Slamberová R. Anxiogenic effect of low-dose methamphetamine in the test of elevated plus-maze. Praque Med. Rep. 2012, 113:223-230.
7. Bananej M., Karimi-Sori A., Zarrindast M.R., Ahmadi S. D1 and D2 dopaminergic systems in the rat basolateral amygdale are involved in anxiogenic-like effects induced by histamine. J. Psychopharmacol. 2012, 26:564-574.
8. Pich E.M., Samanin R. Disinhibitory effects of buspirone and low doses of sulpiride and haloperidol in two experimental anxiety models in rats: possible role of dopamine. Psychopharmacology (Berl.) 1986, 89:125-130.
9. Kuczenski R., Segal D.S. Sensitization of amphetamine-induced stereotyped behaviors during the acute response: role of D1 and D2 dopamine receptors. Brain Res. 1999, 822(March (1-2)):164-174.
10. Shuto T., Kuroiwa M., Hamamura M., Yabuuchi K., Shimazoe T., Watanabe S., Nishi A., Yamamoto T. Reversal of methamphetamine-induced behavioral sensitization by repeated administration of a dopamine D1 receptor agonist. Neuropharmacology 2006, 50(June (8)):991-997.
11. Hamamura T., Akiyama K., Akimoto K., Kashihara K., Okumura K., Ujike H., Otsuki S. Co-administration of either a selective D1 or D2 dopamine antagonist with methamphetamine prevents methamphetamine-induced behavioral sensitization and neurochemical change, studied by in vivo intracerebral dialysis. Brain Res. 1991, 546(April (12)):40-46.
12. Jin G.Z. (-)-Tetrahydropalmatine and its analogues as new dopamine receptor antagonists. Trends Pharmacol. Sci. 1987, 8:81-82.
13. Leung W.C., Zheng H., Huen M., Law S.L., Xue H. Anxiolytic-like action of orally administered dl-tetrahydropalmatine in elevated plusmaze. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:775-779.
14. Yun J. l-tetrahydropalmatine inhibits methamphetamine-induced locomotor activity via regulation of 5-HT neuronal activity and dopamine D3 receptor expression. Phytomedicine 2014, 21:1287-1291.
15. Zhao N., Chen Y., Zhu J., Wang L., Cao G., Dang Y., Yan C., Wang J., Chen T. Levo-tetrahydropalmatine attenuates the development and expression of methamphetamine-induced locomotor sensitization and the accompanying activation of ERK in the nucleus accumbens and caudate putamen in mice. Neuroscience 2014, 258:101-110.
16. Sun H., Zhu L., Yang H., Qian W., Guo L., Zhou S., Gao B., Li Z., Zhou Y., Jiang H., Chen K., Zhen X., Liu H. Asymmetric total synthesis and identication of tetrahydroprotoberberine derivatives as new antipsychotic agents possessing a dopamine D1, D2 and serotonin 5-HT1A multi-action profile. Bioorg. Med. Chem. 2013, 21:856-868.
17. Mo J., Guo Y., Yang Y.S., Shen J.S., Jin G.Z., Zhen X.C. Recent development in studies of l-stephlidine and its analogs: chemistry, pharmacology and clinical implications. Curr. Med. Chem. 2007, 14(28):2996-3002.
18. Wang W., Zhou Y., Sun J., Pan L., Kang L., Dai Z., Yu R., Jin G., Ma L. The effect of l-stepholidine, a novel extract of Chinese herb, on the acquisition, expression, maintenance, and re-acquisition of morphine conditioned place preference in rats. Neuropharmacology 2007, 52:355-361.
19. Yue K., Ma B., Chen L., Tian X., Ru Q., Gan Y., Wang D., Jin G., Li C. l-Stepholidine, a naturally occurring dopamine D1 receptor agonist and D2 receptor antagonist, attenuates heroin self-administration and cue-induced reinstatement in rats. Neuroreport 2014, 25(January (1)):1.
20. Sun Y., Dai J., Hu Z., Du F., Niu W., Wang F., Liu F., Jin G., Li C. Oral bioavailability and brain penetration of (-)-stepholidine, a tetrahydroprotoberberine agonist at dopamine D(1) and antagonist at D(2) receptors, in rats. Br. J. Pharmacol. 2009, 158:1302-1312.
21. Szumlinski K.K., Haskew R.E., Balogun M.Y., Maisonneuve I.M., Glick S.D. Iboga compounds reverse the behavioural disinhibiting and corticosterone effects of acute methamphetamine: implications for their anti-addictive properties. Pharmacol. Biochem. Behav. 2001, 69(July-August (3-4)):485-491.
22. Šlamberová R., Pometlová M., Macúchová E., Nohejlová K., Stuchlík A., Valeš K. Do the effects of prenatal exposure and acute treatment of methamphetamine on anxiety vary depending on the animal model used?. Behav. Brain Res. 2015, 292(July (3)):361-369.
23. Pham M., Raymond J., Hester J., Kyzar E., Gaikwad S., Bruce I., et al. Assessing social behavior phenotypes in adult zebrafish: shoaling, social preference and mirror biting tests. Zebrafish Protocols for Neurobehavioral Research 2012, 231-246. Humana Press, New York, NY. A.V. Kalueff, A.M. Stewart (Eds.).
24. Levin E.D., Bencan Z., Cerutti D.T. Assessing stress in zebrafish: anxiolytic effects of nicotine. Neurotoxicol. Teratol. 2006, 28:709-710.
25. Darland T., Dowling J.E. Behavioral screening for cocaine sensitivity in mutagenized zebrafish. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:11691-11696.
26. Ninkovic J., Bally-Cuif L. The zebrafish as a model system for assessing the reinforcing properties of drugs of abuse. Methods 2006, 39:262-274.
27. Gerlai R. High-throughput behavioral screens: the first step towards finding genes involved in vertebrate brain function using zebrafish. Molecules 2010, 15:2609-2622.
28. Bencan Z., Sledge D., Levin E.D. Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety. Pharmacol. Biochem. Behav. 2009, 94:75-80.
29. Bencan Z., Levin E.D. The role of alpha7 and alpha4 beta2 nicotinic receptors in the -induced anxiolytic effect in zebrash. Physiol. Behav. 2008, 95:408-412.
30. Egan R.J., Bergner C.L., Hart P.C., Cachat J.M., Canavello P.R., Elegante M.F., et al. Understanding behavioral and physiological phenotypes of stress and anxiety in zebrafish. Behav. Brain Res. 2009, 205:38-44.
31. Stewart A., Riehl R., Wong K., Green J., Cosgrove J., Vollmer K., Kyzar E., Hart P., Allain A., Cachat J., Gaikwad S., Hook M., Rhymes K., Newman A., Utterback E., Chang K., Kalueff A.V. Behavioral effects of MDMA ('ecstasy') on adult zebrafish. Behav. Pharmacol. 2011, 22:275-280.
32. Airhart M.J., Lee D.H., Wilson T.D., Miller B.E., Miller M.N., Skalko R.G. Movement disorders and neurochemical changes in zebrafish larvae after bath exposure to fluoxetine (PROZAC). Neurotoxicol. Teratol. 2007, 29:652-664.
33. Jing L., Zhang M., Li J.X., Huang P., Liu Q., Li Y.L., Liang H., Liang J.H. Comparison of single versus repeated methamphetamine injection induced behavioral sensitization in mice. Neurosci Lett. 2014, 560(Feburary (7)):103-106.
34. Bardo M.T., Bevins R.A. Conditioned place preference: what does it add to our preclinical understanding of drug reward?. Psychopharmacology (Berl.) 2000, 153(December (1)):31-43.
35. Funada M., Aoo N. Evaluation of drug dependence: use of a conditioned place preference paradigm. Nihon Yakurigaku Zasshi. 2007 Aug, 130(August (2)):128-133.
36. Ninkovic J., Folchert A., Makhankov Y.V., Neuhauss S.C., Sillaber I., Straehle U., Bally-Cuif L. Genetic identification of AChE as a positive modulator of addiction to the psychostimulant d-amphetamine in zebrafish. J. Neurobiol. 2006, 66(April (5)):463-475.
37. Collier A.D., Echevarria D.J. The utility of the zebrafish model in conditioned place preference to assess the rewarding effects of drugs. Behav. Pharmacol. 2013, 24(September (5-6)):375-383.
38. Parker M.O., Evans A.M., Brock A.J., Combe F.J., Teh M.T., Brennan C.H. Moderate alcohol exposure during early brain development increases stimulus-response habits in adulthood. Addict. Biol. 2014, (August (19)). [Epub ahead of print]. 10.1111/adb.12176.
39. Huang E.Y., Liu T.C., Tao P.L. Co-administration of dextromethorphan with morphine attenuates morphine rewarding effect and related dopamine releases at the nucleus accumbens. Naunyn Schmiedebergs Arch. Pharmacol. 2003, 368:386-392.
40. Prus A.J., James J.R., Rosecrans J.A. Conditioned place preference. Methods of Behavior Analysis in Neuroscience 2009, 59-76. Taylor and Francis Group, Boca Raton, FL. 2nd ed. J.J. Buccafusco (Ed.).
41. Richard Rawson A. Current research on the epidemiology, medical and psychiatric effects, and treatment of methamphetamine use. J. Food Drug Anal. 2013, 21:S77-S81.
42. Ponnusamy R., Nissim H.A., Barad M. Systemic bloced of D2-like dopamine receptors facilitates extinction of condition of conditioned fear in mice. Learn. Mem. 2005, 12:399-406.
43. 1A agonist, S20244, and its enantiomers in mice. Bizot-Espiard J. Neuroreport 1992, 3:84-86.
44. Feighner J.P., Boyer W.F. Serotonin-1A anxiolytics: an overview. Psychopathology 1989, 22(Suppl. 1):21-26.
45. Loane C., Politis M. Buspirone what is it all about?. Brain Res. 2012, 1461:111-118.
46. Goldberg H.L., finnerty R.J. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am. J. Psychiatry 1979, 136:1184-1187.
47. Connors K.A., Valenti T.W., Lawless K., Sackerman J., Onaivi E.S., Brooks B.W., Gould G.G. Similar anxiolytic effects of agonists targeting serotonin 5-HT1A or cannabinoid CB receptors on zebrafish behavior in novel environments. Aquat. Toxicol. 2014, 151:105-113.
48. Carson W.H., Kitagawa H. Drug development for anxiety disorders: new roles for atypical antipsychotics. Psychopharmacol. Bull. 2004, 38:38-45.
49. Boulay D., Depoortere R., Louis C., Lacave M., Lucas M.T., Griebel G. SSR181507, a dopamine D2 receptor and 5-HT1A receptor ligand: evidence for mixed anxiolytic-and antidepressant-like activities. Pharmacol. Biochem. Behav. 2011, 97:428-435.
50. Cuisiat S., Bourdiol N., Lacharme V., Newman-Tancredi A., Colpaert F., Vacher B. Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities. J. Med. Chem. 2007, 50:865-876.
51. Xu W., Wang Y., Ma Z., Chiu Y.T., Huang P., Rasakham K., Unterwald E., Lee D.Y., Liu-Chen L.Y. l-isocorypalmine reduces behavioral sensitization and rewarding effects of cocainein mice by acting on dopamine receptors. Drug Alcohol Depend. 2013, 133(December (2)):693-703.
52. Kitanaka N., Kitanaka J., Takemura M. Behavioral sensitization and alteration in monoamine metabolism in mice after single versus repeated methamphetamine administration. Eur. J. Pharmacol. 2003, 474:63-70.
53. Ago Y., Tanaka T., Kita Y., Tokumoto H., Takuma K., Matsuda T. Lithium attenuates methamphetamine-induced hyperlocomotion and behavioralsensitization via modulation of prefrontal monoamine release. Neuropharmacology 2012 Mar, 62(March (4)):1634-1639.
54. Ichikawa J., Meltzer H.Y. R(+) -8-OH-DPAT, a serotonin (1A) receptor Agonist, potentiated S(-) -sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J. Pharmacol. Exp. Ther. 1999, 291(3):1227-1232.
55. Santiago M., Machado A., Cano J. Regulation of prefrontal cortical dopamine release by dopamine receptor agonists and antagonists. Eur. J. Pharmacol. 1993, 239(1-3):83-91.
56. Liao R.M. Development of conditioned place preference induced by intra-accumbens infusion of amphetamine is attenuated by co-infusion of dopamine D1 and D2receptor antagonists. Pharmacol. Biochem. Behav. 2008, 89(May (3)):367-373.
57. Liu Z.H., Jin W.Q., Zhang H.P., Chen X.J., Jin G.Z. Suppression of morphine-induced conditioned place preference by l-12-chloroscoulerine, a novel dopamine receptor ligand. Pharmacol. Biochem. Behav. 2003, 75(May (2)):289-294.
58. Divac N., Prostran M., Jakovcevski I., Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed. Res. Int. 2014, 2014. 656370.